Studies on the cross resistance of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines.
McGuire
J J
JJ
Roswell Park Cancer Institute, Buffalo, NY 14263.
Heitzman
K J
KJ
Haile
W H
WH
Russell
C A
CA
McCloskey
D E
DE
Piper
J R
JR
D000970:Antineoplastic Agents / Q000633:toxicity*; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002999:Clone Cells; D004351:Drug Resistance; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D005467:Floxuridine / Q000633:toxicity; D005493:Folic Acid Antagonists / Q000633:toxicity*; D006801:Humans; D008727:Methotrexate / Q000633:toxicity*; D010453:Peptide Synthases / Q000172:deficiency*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D005467:Floxuridine; D010453:Peptide Synthases; C023103:folylpolyglutamate synthetase; D008727:Methotrexate